102 related articles for article (PubMed ID: 28219133)
1. [Clinical observation on LOP regimen combined with IMRT treatment for early nasal NK/T cell lymphoma].
Hu YF; Huang YH; Wu T; Zhang Y; Liu XM; Song Y; Gan JY
Zhonghua Yi Xue Za Zhi; 2017 Feb; 97(6):447-450. PubMed ID: 28219133
[No Abstract] [Full Text] [Related]
2. Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma.
Hu Y; Chen M; Song Y; Liu X; Gou F; Zhang J; Huang Y
Am J Clin Oncol; 2020 Apr; 43(4):257-262. PubMed ID: 31764026
[TBL] [Abstract][Full Text] [Related]
3. [Clinical observation of LOP chemotherapy combined with radiotherapy in the treatment of early nasal NK/T cell lymphoma].
Ai WB; Jing QC
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Oct; 33(10):990-992. PubMed ID: 31623051
[No Abstract] [Full Text] [Related]
4. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
5. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of PVD regimen combined with IMRT for early-stage extranodal nasal NK/T-cell lymphoma].
Zhang Y; Huang YH; Hu YF; Liu QL; Wu T
Zhonghua Yi Xue Za Zhi; 2017 Jul; 97(26):2047-2049. PubMed ID: 28763877
[No Abstract] [Full Text] [Related]
7. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
8. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
Yong W; Zheng W; Zhang Y
Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
[TBL] [Abstract][Full Text] [Related]
12. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma.
Yong W; Zheng W; Zhang Y; Zhu J; Wei Y; Zhu D; Li J
Int J Hematol; 2003 Aug; 78(2):163-7. PubMed ID: 12953813
[TBL] [Abstract][Full Text] [Related]
13. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
Yong W; Zheng W; Zhu J; Zhang Y; Wang X; Xie Y; Lin N; Xu B; Lu A; Li J
Ann Hematol; 2009 Jul; 88(7):647-52. PubMed ID: 19107482
[TBL] [Abstract][Full Text] [Related]
14. [Long-term effect of risk-adaptive therapy for early stage extranodal NK/T cell lymphoma].
Wu T; Liu QL; Hu YF; Zhang J; Chen MX; Chen XX; Huang YH; Lu B
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):859-864. PubMed ID: 31770855
[No Abstract] [Full Text] [Related]
15. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus.
Zhao Q; Fan S; Chang Y; Liu X; Li W; Ma Q; Li Y; Wang Y; Zhang L; Zhang M
Cancer Manag Res; 2019; 11():3555-3564. PubMed ID: 31118779
[No Abstract] [Full Text] [Related]
17. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
[TBL] [Abstract][Full Text] [Related]
18. L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma.
Obama K; Tara M; Niina K
Int J Hematol; 2003 Oct; 78(3):248-50. PubMed ID: 14604284
[TBL] [Abstract][Full Text] [Related]
19. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma.
Wang H; Li YX; Wang WH; Jin J; Dai JR; Wang SL; Liu YP; Song YW; Wang ZY; Liu QF; Fang H; Qi SN; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1115-21. PubMed ID: 21514070
[TBL] [Abstract][Full Text] [Related]
20. Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.
Ghione P; Qi S; Imber BS; Seshan V; Moskowitz A; Galasso N; Lunning M; Straus D; Sauter C; Dahi P; Dogan A; Yahalom J; Horwitz S
Leuk Lymphoma; 2020 Dec; 61(14):3331-3341. PubMed ID: 32844695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
